DXCM DexCom, Inc.
QT68Latest market price
77.94
-0.38-0.49%
TA
Loading chart...
Snapshot
| Index | S&P 500, NDX | P/E | 30.81 | EPS (ttm) | 2.53 | Insider Own | 0.83% | Shs Outstand | 377.36M | Perf Week | -9.41% |
| Market Cap | 29.41B | Forward P/E | 24.91 | EPS next Y | 3.13 | Insider Trans | -4.89% | Shs Float | 376.00M | Perf Month | -10.90% |
| Enterprise Value | 28.84B | PEG | 1.81 | EPS next Q | - | Inst Own | 94.03% | Short Float | 3.73% | Perf Quarter | 6.23% |
| Income | 1.00B | P/S | 5.92 | EPS this Y | 29.70% | Inst Trans | 0.00% | Short Ratio | 3.06 | Perf Half Y | 26.59% |
| Sales | 4.97B | P/B | 11.22 | EPS next Y | 17.08% | ROA | 15.49% | Short Interest | 14.02M | Perf YTD | 17.43% |
| Book/sh | 6.95 | P/C | 15.11 | EPS next 5Y | 17.06% | ROE | 36.19% | 52W High | 92.59 -15.82% | Perf Year | 10.24% |
| Cash/sh | 5.16 | P/FCF | 20.93 | EPS past 3/5Y | 37.73% 10.48% | ROIC | 21.60% | 52W Low | 54.11 44.04% | Perf 3Y | -7.35% |
| Dividend Est. | - | EV/EBITDA | 18.49 | Sales past 3/5Y | 17.01% 19.33% | Gross Margin | 62.47% | Volatility | 3.46% 2.78% | Perf 5Y | -42.74% |
| Dividend TTM | - | EV/Sales | 5.80 | EPS Y/Y TTM | 78.17% | Oper. Margin | 22.92% | ATR (14) | 2.61 | Perf 10Y | 280.20% |
| Dividend Ex-Date | - | Quick Ratio | 1.43 | Sales Y/Y TTM | 23.21% | Profit Margin | 20.12% | RSI (14) | 32.06 | Recom | 2.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | EPS Q/Q | 45.83% | SMA20 | -7.80% | Beta | 1.44 | Target Price | 96.14 |
| Payout | 0.00% | Debt/Eq | 0.50 | Sales Q/Q | 13.05% | SMA50 | -10.23% | Rel Volume | 1.15 | Prev Close | 78.32 |
| Employees | 11,050 | LT Debt/Eq | 0.50 | Earnings | Oct 29 | SMA200 | 4.89% | Avg Volume | 4.53M | Price | 77.94 |
| IPO Date | Apr 14, 2005 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.59% 1.40% | Net Debt/EBITDA | 0.19 | Volume | 5,215,003 | Change | -0.49% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | Mizuho Securities | Outperform | $95 → $100 |
| Oct-06-26 | Initiated | Barclays | Overweight | $64 → $115 |
| Oct-01-26 | Reiterated | RBC Capital | Outperform | $90 → $105 |
| Sep-18-26 | Reiterated | Truist Securities | Buy | $93 → $102 |
| Aug-04-26 | Reiterated | Argus Research | Buy | $96 |
| Aug-03-26 | Reiterated | Canaccord Genuity | Buy | $82 → $90 |
| Jul-31-26 | Reiterated | Raymond James | Strong Buy | $91 → $94 |
| Jul-31-26 | Reiterated | Robert W. Baird | $80 → $105 | |
| Jul-31-26 | Reiterated | Stifel Nicolaus | Buy | $90 → $95 |
| Jul-31-26 | Reiterated | RBC Capital | Outperform | $85 → $90 |
Latest News· Times ET
Oct-21-26
Oct-21-2605:49PM
Oct-20-26
04:55AM
Oct-17-26
Oct-17-2611:41PM
Oct-16-26
Oct-15-26
Oct-15-2607:30PM
Oct-14-26
Oct-14-2605:10PM
Oct-13-26
Oct-08-26
Oct-06-26
02:00PM
Oct-02-26
Sep-29-26
Company
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Ownership
Total institutional ownership94.03%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,969 | 4,662 | 4,033 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,865 | 1,860 | 1,595 | — | — | — | — | — | — | |
| Gross Profit | 3,104 | 2,802 | 2,438 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,362 | 1,291 | 1,286 | — | — | — | — | — | — | |
| Research and Development | 604 | 599 | 552 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 1,139 | 912 | 600 | — | — | — | — | — | — | |
| Interest Expense | 15 | 18 | 19 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 156 | 195 | 128 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,281 | 1,088 | 709 | — | — | — | — | — | — | |
| Income Taxes | 280 | 252 | 133 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,000 | 836 | 576 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,000 | 836 | 576 | — | — | — | — | — | — | |
| Net Income | 1,000 | 836 | 576 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.59 | 2.14 | 1.46 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.59 | 2.14 | 1.46 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.53 | 2.09 | 1.42 | — | — | — | — | — | — | |
| EBITDA | 1,560 | 1,359 | 946 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.81 | 31.76 | 54.77 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.02 | 5.55 | 7.81 | — | — | — | — | — | — | |
| Gross Margin | 62.47 | 60.10 | 60.45 | — | — | — | — | — | — | |
| Operating Margin | 22.92 | 19.56 | 14.88 | — | — | — | — | — | — | |
| Net Margin | 20.12 | 17.93 | 14.28 | — | — | — | — | — | — | |
| Shares Outstanding | 384 | 390 | 405 | — | — | — | — | — | — | |
| Market Capitalization | 29,929 | 25,884 | 31,497 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brown Michael Jon | EVP Chief Legal Compliance Off | Oct 15 '26 | Sale | 85.48 | 1,700 | 145,316 | 98,185 | Oct 19 |
| Stern Sadie | EVP Chief People & Culture Off | Sep 28 '26 | Sale | 86.15 | 2,565 | 220,975 | 123,478 | Sep 30 |
| AUGUSTINOS NICHOLAS | Director | Sep 15 '26 | Sale | 84.04 | 6,539 | 549,538 | 29,293 | Sep 16 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | Sep 15 '26 | Sale | 84.04 | 1,700 | 142,868 | 99,885 | Sep 16 |
| AUGUSTINOS NICHOLAS | Director | Sep 14 '26 | Sale | 84.02 | 1,550 | 130,231 | 35,832 | Sep 16 |
| Sylvain Jereme M | EVP, Chief Financal Officer | Sep 10 '26 | Sale | 83.27 | 3,638 | 302,936 | 146,828 | Sep 14 |
| Stern Sadie | EVP Chief People & Culture Off | Aug 27 '26 | Sale | 88.37 | 2,565 | 226,669 | 126,043 | Aug 28 |
| SAYER KEVIN R | Executive Chair | Aug 20 '26 | Sale | 90.01 | 26,756 | 2,408,242 | 302,214 | Aug 24 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | Aug 14 '26 | Sale | 91.93 | 1,700 | 156,281 | 102,953 | Aug 17 |
| Heller Bridgette P | Director | Aug 12 '26 | Sale | 88.29 | 1,012 | 89,349 | 29,570 | Aug 13 |
| FOLETTA MARK G | Director | Aug 03 '26 | Sale | 85.32 | 2,000 | 170,640 | 48,852 | Aug 04 |
| FOLETTA MARK G | Director | Jul 31 '26 | Sale | 80.00 | 2,000 | 160,000 | 50,852 | Aug 04 |
| SAYER KEVIN R | Executive Chair | Jul 20 '26 | Sale | 76.32 | 26,756 | 2,041,999 | 328,970 | Jul 21 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | Jul 15 '26 | Sale | 74.42 | 1,700 | 126,514 | 104,653 | Jul 16 |
| SAYER KEVIN R | Executive Chair | Jul 06 '26 | Sale | 72.00 | 26,756 | 1,926,432 | 355,726 | Jul 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.